跳至主要内容
临床试验/ACTRN12619000952145
ACTRN12619000952145终止未知

I-Move: A randomised controlled pilot trial of a personalised, semi-supervised exercise intervention to reduce fatigue for patients receiving immunotherapy for stage IV Melanoma

Peter MacCallum Cancer Centre0 个研究点目标入组 13 人开始时间: 2019年7月8日最近更新:
适应症

试验速览

阶段
未知
状态
终止
发起方
入组人数
13

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Aged 18 years or older
  • Diagnosis of stage IV Melanoma
  • Scheduled to commence receiving single agent Ipilimumab, Nivolumab or Pembrolizumab; or combination Ipilimumab and Nivolumab immunotherapy, and have not yet had their second infusion
  • Able to speak and read English
  • Deemed suitable to take part in an exercise intervention by their treating clinician
  • Access to a smartphone

排除标准

  • ECOG performance >2
  • Physical/Safety Assessment:
  • Peripheral Neuropathy: An assigned WHO Grade of 3 or above will preclude participation in the trial.
  • Contra-indications to exercise testing including the following
  • oMyocardial infarction or unstable angina in last 3 months
  • oCerebrovascular event or transient ischemic attack in last 3 months
  • oPulmonary embolic event within 3 months, existing acute or chronic deep vein thrombosis
  • oPresentation with active sepsis

研究者

发起方
Peter MacCallum Cancer Centre

相似试验

I-Move: A randomised controlled pilot trial of a... | 临床试验